Daily ASA therapy after PCI for patients without ASA ‘‘resistance,’’ but no definition of resistance is offered.
Class IIb, level C recommendation
For clopidogrel, the guidelines state that ‘‘ . . .in patients in whom stent thrombosis may be catastrophic or lethal. . . Platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated.’’ What about GRAVITAS???
Method to assess platelet inhibition is not described.